Carboranyl-1,8-naphthalimide intercalators induce lysosomal membrane permeabilization and ferroptosis in cancer cell lines

References

• Kamal A, Bolla NR, Srikanth PS, Srivastava AK. Naphthalimide derivatives with therapeutic characteristics: a patent review. Expert Opin Ther Pat. 2013;23(3):299–317.
   PubMed Web of Science ®Google Scholar
• Braña M, Ramos A. Naphthalimides as anticancer agents: synthesis and biological activity. Curr Med Chem Anticancer Agents. 2001;1(3):237–255.
   PubMedGoogle Scholar
• Tandon R, Luxami V, Kaur H, Tandon N, Paul K. 1,8-Naphthalimide: a potent DNA intercalator and target for cancer therapy. Chem Rec. 2017;17(10):956–993.
   PubMed Web of Science ®Google Scholar
• Shen K, Sun L, Zhang H, Xu Y, Qian X, Lu Y, Li Q, Ni L, Liu J. A ROS-mediated lysosomal-mitochondrial pathways is induced by a novel Amonafide analogue, 7c, in human HeLa cervix carcinoma cells. Cancer Lett. 2013;333(2):229–238.
   PubMed Web of Science ®Google Scholar
• Pain A, Samanta S, Dutta S, Saxena AK, Shanmugavel M, Kampasi H, Quazi GN, Sanyal U. Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compound. Acta Pol Pharm. 2003;60(4):285–291.
   PubMedGoogle Scholar
• Dai F, Li Q, Wang Y, Ge C, Feng C, Xie S, He H, Xu X, Wang C. Design, synthesis, and biological evaluation of mitochondrial-targeted flavone-naphthalimide-polyamine conjugates with antimetastatic activity. J Med Chem. 2017;60(5):2071–2083.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liang X, Zhang H, Xie H, Liu J, Xu Y, Zhu W, Wang Y, Wang X, Tan S, et al. A new class of naphthalimide-based antitumor agents that inhibit Topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem. 2010;53(6):2589–2600.
   PubMed Web of Science ®Google Scholar
• Tomczyk MD, Byczek-Wyrostek A, Strama K, Wawszków M, Kasprzycki P, Walczak KZ. Anticancer activity and Topoisomerase II inhibition of naphthalimides with ω-hydroxylalkylamine side-chains of different lengths. Med Chem. 2019;15(5):550–560.
   PubMed Web of Science ®Google Scholar
• Tomczyk MD, Walczak KZ. 1,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017. Eur J Med Chem. 2018;159:393–422.
   PubMed Web of Science ®Google Scholar
• Tandon R, Luxami V, Tandon N, Paul K. Recent developments on 1,8-naphthalimide moiety as potential target for anticancer agents. Bioorg Chem. 2022;121:105677.
   PubMed Web of Science ®Google Scholar
• Nekvinda J, Różycka D, Rykowski S, Wyszko E, Fedoruk-Wyszomirska A, Gurda D, Orlicka-Płocka M, Giel-Pietraszuk M, Kiliszek A, Rypniewski W, et al. Synthesis of naphthalimide-carborane and metallacarborane conjugates: anticancer activity, DNA binding ability. Bioorg Chem. 2020;94:103432.
   PubMed Web of Science ®Google Scholar
• Rykowski S, Gurda-Woźna D, Orlicka-Płocka M, Fedoruk-Wyszomirska A, Giel-Pietraszuk M, Wyszko E, Kowalczyk A, Stączek P, Bak A, Kiliszek A, et al. Design, synthesis, and evaluation of novel 3-carboranyl-1,8-naphthalimide derivatives as potential anticancer agents. IJMS. 2021;22(5):2772.
   Google Scholar
• Rykowski S, Gurda-Woźna D, Orlicka-Płocka M, Fedoruk-Wyszomirska A, Giel-Pietraszuk M, Wyszko E, Kowalczyk A, Stączek P, Biniek-Antosiak K, Rypniewski W, et al. Design of DNA intercalators based on 4-carboranyl-1,8-naphthalimides: investigation of their DNA-binding ability and anticancer activity. IJMS. 2022;23(9):4598.
   Google Scholar
• Leśnikowski ZJ. Challenges and opportunities for the application of boron clusters in drug design. J Med Chem. 2016;59(17):7738–7758.
   PubMed Web of Science ®Google Scholar
• Leśnikowski ZJ. Recent developments with boron as a platform for novel drug design. Expert Opin Drug Discov. 2016;11(6):569–578.
   PubMed Web of Science ®Google Scholar
• Różycka D, Leśnikowski ZJ, Olejniczak AB. Synthesis of boron cluster analogs of penicillin and their antibacterial activity. J Organomet Chem. 2019;881(15):19–24.
   Google Scholar
• Messner K, Vuong B, Tranmer GK. The boron advantage: the evolution and diversification of boron’s applications in medicinal chemistry. Pharmaceuticals. 2022;15(3):264.
   Web of Science ®Google Scholar
• Fink K, Uchman M. Boron clusters compounds as new chemical leads for antimicrobial therapy. Coord Chem Rev. 2021;431:213684.
   Web of Science ®Google Scholar
• Das BC, Nandwana NK, Das S, Nandwana V, Shareef MA, Das Y, Saito M, Weiss LM, Almaguel F, Hosmane NS, et al. Boron chemical in drug discovery and development: synthesis and medicinal perspective. Molecules. 2022;27(9):2615.
   PubMed Web of Science ®Google Scholar
• Chen Y, Du F, Tang L, Xu J, Zhao Y, Wu X, Li M, Shen J, Wen Q, Cho CH, et al. Carboranes as unique pharmacophores in antitumor medicinal chemistry. Mol Ther Oncolytics. 2022;24:400–416.
   PubMed Web of Science ®Google Scholar
• Marfavi A, Kavianpour P, Rendina LM. Carboranes in drug discovery, chemical biology and molecular imaging. Nat Rev Chem. 2022;6(7):486–504.
   PubMed Web of Science ®Google Scholar
• Bogucka-Kocka A, Kołodziej P, Makuch-Kocka A, Różycka D, Rykowski S, Nekvinda J, Grüner B, Olejniczak AB. Nematicidal activity of naphthalimide-boron cluster conjugates. Chem Commun (Camb). 2022;58(15):2528–2531.
   PubMed Web of Science ®Google Scholar
• Olejniczak AB, Adamska AM, Paradowska E, Studzińska M, Suski P, Leśnikowski ZJ. Modification of selected anti-HCMV drugs with lipophilic boron cluster modulator. Acta Pol Pharm–Drug Res. 2013;70(3):489–504.
   PubMed Web of Science ®Google Scholar
• Ibrahim MK, Taghour MS, Metwaly AM, Belal A, Mehany ABM, Elhendawy MA, Radwan MM, Yassin AM, El-Deeb NM, Hafez EE, ElSohly MA, Eissa IH. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Eur J Med Chem. 2018;155:117–134.
   PubMed Web of Science ®Google Scholar
• Abbass EM, Khalil AK, Mohamed MM, Eissa IH, El-Naggar AM. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers. Bioorg Chem. 2020;104:104255.
   PubMed Web of Science ®Google Scholar
• Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem. 2022;37(1):299–314.
   PubMed Web of Science ®Google Scholar
• Reddy TN, Beatriz A, Rao VJ, de Lima DP. Carbonyl compounds’ journey to amide bond formation. Chem Asian J. 2019;14(3):344–388.
   PubMed Web of Science ®Google Scholar
• Malmquist J, Sjöberg S. Asymmetric synthesis of p-carboranylalanine (p-Car) and 2-methyl-o-carboranylalanine (Me-o-Car). Tetrahedron. 1996;52(27):9207–9218.
   Web of Science ®Google Scholar
• Naeslund C, Ghirmai S, Sjöberg S. Enantioselective synthesis of m-carboranylalanine, a boron rich analogue of phenylalanine. Tetrahedron. 2005;61(5):1181–1186.
   Web of Science ®Google Scholar
• Afanasyev OI, Kuchuk E, Usanov DL, Chusov D. Reductive amination in the synthesis of pharmaceuticals. Chem Rev. 2019;119(23):11857–11911.
   PubMed Web of Science ®Google Scholar
• Dozzo P, Kasar RA, Kahl SB. Simple, high-yield methods for the synthesis of aldehydes directly from o-, m-, and p-carborane and their further conversions. Inorg Chem. 2005;44(22):8053–8057.
   PubMed Web of Science ®Google Scholar
• Mergny JL, Duval-Valentin G, Nguyen CH, Perrouault L, Faucon B, Rougée M, Montenay-Garestier T, Bisagni E, Hélène C. Triple helix-specific ligands. Science. 1992;256(5064):1681–1684.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Sasikala WB. Drug-DNA intercalation: from discovery to the molecular mechanism. Adv Protein Chem Struct Biol. 2013;92:1–62.
   PubMed Web of Science ®Google Scholar
• Jolley EA, Hardebeck LKE, Ren Y, Adams MS, Lewis M, Znosko BM. The effects of varying the substituent and DNA sequence on the stability of 4-substituted DNA-naphthalimide complexes. Biophys Chem. 2018;239:29–37.
   PubMed Web of Science ®Google Scholar
• Jiang H, Shang L, Wang ZX, Dong SJ. Spectrometric and voltammetric investigation of interaction of neutral red with calf thymus DNA: pH effect. Biophys Chem. 2005;118(1):42–50.
   PubMed Web of Science ®Google Scholar
• Kong D-M, Wang J, Zhu L-N, Jin Y-W, Li X-Z, Shen H-X, Mi H-F. Oxidative DNA cleavage by Schiff base tetraazamacrocyclic oxamido nickel(II) complexes. J Inorg Biochem. 2008;102(4):824–832.
   PubMed Web of Science ®Google Scholar
• Sirajuddin M, Ali S, Badshah A. Drug-DNA interactions and their study by UV-Visible, fluorescence spectroscopic and cyclic voltammetry. J Photochem Photobiol B-Biol. 2013;124:1–19.
   PubMed Web of Science ®Google Scholar
• Inoue S, Salah-Eldin AE, Omoteyama K. Apoptosis and anticancer drug resistance. Hum Cell. 2001;14(3):211–221.
   PubMedGoogle Scholar
• Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408–9421.
   PubMed Web of Science ®Google Scholar
• Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012;226(2):352–364.
   PubMed Web of Science ®Google Scholar
• Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012;19(3):369–377.
   PubMed Web of Science ®Google Scholar
• Trepat X, Chen Z, Jacobson K. Cell Migration. Compr Physiol. 2012;2(4):2369–2392.
   PubMed Web of Science ®Google Scholar
• Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017;22(11):1321–1335.
   PubMed Web of Science ®Google Scholar
• Dabiri Y, Schmid A, Theobald J, Blagojevic B, Streciwilk W, Ott I, Wölfl S, Cheng X. A ruthenium(II) N-heterocyclic carbene (NHC) complex with naphthalimide ligand triggers apoptosis in colorectal cancer cells via activating the ROS-p38 MAPK pathway. IJMS. 2018;19(12):3964.
   Google Scholar
• Liu T, Sun L, Zhang Y, Wang Y, Zheng J. Imbalanced GHS/ROS and sequential cell death. J Biochem Mol Toxicol. 2022;36(1):e22942.
   PubMed Web of Science ®Google Scholar
• Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR. Relation between mitochondrial membrane potential and ROS formation. In: Palmeira CM, Moreno AJ, editors. Mitochondrial Bioenergetics. New York (USA): Humana Press; 2011. p. 183–205.
   Google Scholar
• Andrés-Juan C, de la Lastra P, Plou JM, Pérez-Lebeña FJ. E. The chemistry of Reactive Oxygen Species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. IJMS. 2021;22(9):4642.
   Google Scholar
• Chen X, Kang R, Kroemer G, Tang D. Organelle-specific regulation of ferroptosis. Cell Death Differ. 2021;28(10):2843–2856.
   PubMed Web of Science ®Google Scholar
• Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401–2421.
   PubMed Web of Science ®Google Scholar
• Li B, Yang L, Peng X, Fan Q, Wei S, Yang S, Li X, Jin H, Wu B, Huang M, et al. Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers. Biomed Pharmacother. 2020;130:110710.
   PubMed Web of Science ®Google Scholar
• Gleitze S, Paula-Lima A, Núnez MT, Hidalgo C. The calcium–iron connection in ferroptosis-mediated neuronal death. Free Radic Biol Med. 2021;175:28–41.
   PubMed Web of Science ®Google Scholar
• Serrano-Puebla A, Boya P. Lysosomal membrane permeabilization as a cell death mechanism in cancer cells. Biochem Soc Trans. 2018;46(2):207–215.
   PubMedGoogle Scholar
• Villamil Giraldo AM, Appelqvist H, Ederth T, Ollinger K. Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death. Biochem Soc Trans. 2014;42(5):1460–1464.
   PubMed Web of Science ®Google Scholar
• Wang F, Gomez-Sintes R, Boya P. Lysosomal membrane permeabilization and cell death. Traffic. 2018;19(12):918–931.
   PubMed Web of Science ®Google Scholar
• Torii S, Shintoku R, Kubota C, Yaegashi M, Torii R, Sasaki M, Suzuki T, Mori M, Yoshimoto Y, Takeuchi T, et al. An essential role for functional lysosomes in ferroptosis of cancer cells. Biochem J. 2016;473(6):769–777.
   PubMedGoogle Scholar
• Gao H, Bai Y, Jia Y, Zhao Y, Kang R, Tang D, Dai E. Ferroptosis is a lysosomal cell death process. Biochem Biophys Res Commun. 2018;503(3):1550–1556.
   PubMed Web of Science ®Google Scholar
• Awad D, Damian L, Winterhalter M, Karlsson G, Edwards K, Gabel D. Interaction of Na2B12H11SH with dimyristoyl phosphatidylcholine liposomes. Chem Phys Lipids. 2009;157(2):78–85.
   PubMed Web of Science ®Google Scholar
• Barba-Bon A, Salluce G, Lostalé-Seijo I, Assaf KI, Hennig A, Montenegro J, Nau WM. Boron clusters as broadband membrane carriers. Nature. 2022;603(7902):637–642.
   PubMed Web of Science ®Google Scholar
• Verdia-Baguena C, Alcaraz A, Aguilella VM, Cioran AM, Tachikawa S, Nakamura H, Teixidor F, Vinas C. Amphiphilic COSAN and I2-COSAN crossing synthetic lipid membranes: planar bilayers and liposomes. Chem Commun (Camb)). 2014;50(51):6700–6703.
   PubMed Web of Science ®Google Scholar
• Assaf KI, Begaj B, Frank A, Nilam M, Mougharbel AS, Kortz U, Nekvinda J, Gruner B, Gabel D, Nau WM. High-Affinity binding of metallacarborane cobalt bis(dicarbollide) anions to cyclodextrins and application to membrane translocation. J Org Chem. 2019;84(18):11790–11798.
   PubMed Web of Science ®Google Scholar
• Rokitskaya TI, Khailova LS, Makarenkov AV, Shunaev AV, Tatarskiy VV, Shtil AA, Ol’shevskaya VA, Antonenko YN. Carborane derivatives of 1,2,3-triazole depolarize mitochondria by transferring protons through the lipid part of membranes. Biochim Biophys Acta-Rev Biomembr. 2019;1861(3):573–583.
   PubMed Web of Science ®Google Scholar
• Gutierrez EM, Seebacher N, Arzuman L, Kovacevic Z, Lane D, Richardson V, Merlot A, Lok H, Kalinowski D, Sahni S, et al. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochim Biophys Acta. 2016;1863(7):1665–1681.
   PubMed Web of Science ®Google Scholar
• Stark M, Silva TFD, Levin G, Machuqueiro M, Assaraf YG. The lysosomotropic activity of hydrophobic weak base drugs is mediated via their intercalation into the lysosomal membrane. Cells. 2020;9(5):1082.
   PubMed Web of Science ®Google Scholar
• Piao S, Amaravadi RK. Targeting the lysosome in cancer. Ann N Y Acad Sci. 2016;1371(1):45–54.
   PubMedGoogle Scholar
• Iulianna T, Kuldeep N, Eric F. The Achilles’ heel of cancer: targeting tumors via lysosome induced immunogenic cell death. Cell Death Dis. 2022;13(5):509.
   PubMed Web of Science ®Google Scholar
• Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369–413.
   PubMed Web of Science ®Google Scholar
• Sheldrick GM. SHELXT - Integrated space-group and crystal-structure determination. Acta Crystallogr A Found Adv. 2015;71(1):3–8.
   PubMed Web of Science ®Google Scholar
• Sheldrick GM. Crystal structure refinement with SHELXL. Acta Crystallogr C Struct Chem. 2015;71(1):3–8.
   PubMed Web of Science ®Google Scholar
• Braña MF, Castellano JM, Roldan CM, Santos A, Vazquez D, Jimenez A. Synthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic. Cancer Chemother Pharmacol. 1980;4(1):61–66.
   Google Scholar
• Nie MY, Wang Y, Li HL. Electrochemical and spectral properties of phenylhydrazine in the presence of ß-cyclodextrin. Pol J Chem. 1997;71:816–822.
   Google Scholar